Skip to main content
Up to 53% offSee the plans

News | Stocks | Iran

Zahravi Pharmaceutical (DZAH) Lifts Six-Month Net Profit 313% to 6,386 Billion Rials From 1,546 Billion

Sahmino Newsroom | 16 November 2026 | 4 days ago

DZAHup2.9%6,400rials18 November

In its interim financial statements for the six months to 31 Shahrivar 1405 (22 September 2026), filed on Codal on 25 Aban 1405 (16 November 2026), Zahravi Pharmaceutical (DZAH) reported operating revenue of 17,123 billion rials, 136% above the 7,270 billion rials of the same period a year earlier (restated). Cost of sales was 7,051 billion rials, gross profit rose 222% to 10,072 billion rials, and operating profit reached 8,733 billion rials.

Net profit was 6,386 billion rials against 1,546 billion rials a year earlier, an increase of 313%. Basic earnings per share were 601 rials against 145 rials, and share capital stayed unchanged at 10,634 billion rials. The current-period column in the form is labelled "for submission to the auditor". The figures are from the company's standalone income statement.

Reference:CodalThe original report

Sahmino context

What the prices have done since this story was published, and what Sahmino wrote around it

Sahmino's reading

The gross margin rose from about 43% of revenue to about 59% (Sahmino's own calculation from the same income statement); the tax charge was 1,872 billion rials, against 437 billion rials a year earlier.

Since this story was published, DZAH rose 0.2 percent, to 6,360 rials.

Over the same days, Tehran Stock Exchange Index fell 1.4 percent, to 8,392,018.

Over the same days, US Dollar rose 0.5 percent, to 2,699,700 rials.

DZAH
+0.2%
Tehran Stock Exchange Index
−1.4%
US Dollar
+0.5%

Prices to the close of 19 November

More from this market